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Introduction Acute Myeloid Leukemia: Current Landscape
Acute myeloid leukemia (AML) is a hematopoietic clonal stem cell disorder characterized by abnormal differentiation and proliferation of immature blast cells in the bone marrow. AML is defined as ≥20% blasts in the bone marrow or <20% blasts with recurrent cytogenetic abnormalities, according to the 2008 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia (1, 2) .
AML accounts for approximately 80% of all adult leukemia cases, and incidence increases with age, with a median age at diagnosis of 67 years (3). AML may arise de novo by transformation of the hematopoietic stem cell or progenitor cells of the myeloid lineage (4) . Secondary AML can develop as a consequence of chemoradiotherapy or evolution of preexisting myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN). Both forms of secondary AML are associated with unfavorable chromosomal abnormalities and worse prognosis as compared to de novo AMLs (5) . The primary goal of AML therapy is to achieve complete remission (CR) with induction chemotherapy, defined as bone marrow blasts <5%, neutrophil count >1.0 × 10 9 /L, and platelet count >100 × 10 9 /L independent of transfusion (6) . Recent improvements in chemotherapeutic agents and supportive care have resulted in CR rates as high as 85% in patients with AML. However, relapse occurs frequently as approximately 50% to 70% of AML patients who achieve CR as a result of frontline therapy will experience relapse within 3 years (7) . As a result, consolidation chemotherapy or allogeneic stem cell transplantation is often used to prevent relapse, with varying degrees of success.
In spite of advances in therapeutic options, overall patient survival rate has not markedly improved, and AML therapy remains an area of unmet medical need. A large proportion of patients with AML display mutations that lead to signaling pathway dysregulation. The most well-known of these mutations is the FMS-like tyrosine kinase-3 (FLT3) mutation, which occurs in approximately 30% of patients with AML.
The FLT3 mutation is generated by either internal tandem duplication of the juxtamembrane domain or point mutations within the tyrosine kinase domain, both resulting in constitutive activation of tyrosine kinase (8, 9) .
The JAK/STAT Pathway
The JAK/STAT pathway has increasingly been implicated in the pathogenesis of AML. The Janus kinases (JAKs) and downstream components of the pathway are involved in cellular proliferation and differentiation and immunologic regulation. In humans, the JAK family of nonreceptor tyrosine kinases consists of four known members: JAK1, JAK2, JAK3, and TYK2 (10). JAK1, JAK2, and TYK2 are ubiquitously expressed, whereas JAK3 is expressed exclusively in hematopoietic, vascular smooth Activated STATs homodimerize or heterodimerize and translocate into the nucleus to induce transcription of various downstream targets ( Fig. 1) (10) . Transcriptional targets of the JAK-activated STAT family, specifically STAT3 and STAT5, include genes involved in the regulation of cell survival, proliferation, and differentiation, including MYC, cyclin D1, survivin, and BCL2 (9, 12, 13) . Thus, abnormal activation of the JAK/STAT pathway is thought to play an important role in the pathogenesis of some malignancies, and it is becoming increasingly clear that the STATs also play roles in both the intrinsic and extrinsic cancer-associated inflammatory microenvironment (14, 15) .
JAK Dysregulation in Myeloproliferative Neoplasms
Aberrant JAK/STAT hyperactivation and its role in cancer biology have been best defined with respect to hematopoietic malignancies, including MPNs such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) In 2005, the JAK2 V617F gain-of-function mutation was discovered and observed in >90% of patients with PV and >50% of patients with PMF and ET (16) (17) (18) (19) .
Additional JAK2 activating mutations have been observed in the clinic. Furthermore, MPNs have shown the abnormal elevation of several cytokines including serum interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), and tumor necrosis factor-(TNF)-α, which result in the activation of the JAK2 signaling pathway (20, 21) . JAK/STAT dysregulation through JAK2-activating mutations, the release of JAK2-activating cytokines from stromal cells, or the autocrine-loop of JAK2-mediated cytokine production has been postulated as a possible mechanism by which MPNs sustain their proliferative and cyto-protective advantage (22, 23) . and -II studies, in which ruxolitinib therapy resulted in pronounced reductions in splenomegaly as well as improvements in disease-related symptoms compared to both placebo and best available therapy (24, 25) .
A follow-up in both the phase 1/2 251 study and the COMFORT-I study reported an overall survival advantage in the ruxolitinib arm (24, 26) . In the COMFORT-I study, an unplanned survival analysis during a planned safety update revealed that ruxolitinib significantly increased overall survival compared with placebo (13 [8.4%] 
Myeloproliferative Neoplasm Progression to AML
It has been established that patients with an MPN are at an elevated risk for leukemic transformation.
Progression to AML occurs in a subset of patients with an MPN, but progression to acute lymphoblastic leukemia is uncommon (27) . Leukemic transformation may be secondary to the use of cytoreductive therapy, such as hydroxyurea; however, this hypothesis remains controversial (28) . Another hypothesis is that progression to acute leukemia occurs through additional acquisition of key genetic mutations, which provide a survival or proliferative advantage similar to that observed in the progression of chronic myeloid leukemia from chronic phase to blast crisis (29, 30) . The Role of JAK in AML 7 (34-37). Recently, it was shown that mutations in the serine/arginine-rich splicing factor 2 (SRSF2) gene are more prevalent in patients with AML that has progressed from a preexisting MPN than in patients with de novo AML (18.9% and 5.6%, respectively) (38) .
In the clinic, the overall survival rates of patients whose AML progresses from MPN are inferior to those of patients with de novo AML (29) . Leukemic transformation occurs in approximately 15% of patients with primary myelofibrosis, 10% of those with PV, and 4% of those with ET ( Fig. 2) (39-43) . Not surprisingly, the JAK2 V617F mutation is found in a significant percentage of patients with AML arising from a preexisting MPN (44, 45) . Conversely, fewer than 10% of patients with de novo AML harbor the mutation (46) . However, there is evidence that JAK2 V617F-positive MPNs can progress to JAK2 V617F-negative AML at disease transformation (47) . Work by Theocharides et al suggested that JAK2 V617F-positive MPN progression to JAK2 V617F-negative AML occurs through clonal evolution of a common JAK2 V617F-negative progenitor (47) . Interestingly, patients with V617F-negative AML who previously had a V617F-positive MPN had a significantly shorter interval between MPN diagnosis and AML transformation than those who developed V617F-positive AML. Furthermore, patients whose V617F-positive MPN progressed to V617F-positive AML had a greater than 50% V617F positive-tonegative allelic ratio in blasts, indicating that high allelic burden may be an important factor in the clonal evolution to JAK2 V617F-positive AML.
The prognostic implication of JAK2 V617F in this setting remains unclear. One study reported a significantly inferior survival in JAK-mutated AML, whereas other studies have not detected any prognostic or predictive implications (48) (49) (50) . Currently, no well-defined treatment is available for AML arising from a preexisting MPN, and such patients would likely receive standard de novo AML therapies or be referred to a clinical trial.
Rationale for Targeting JAK/STAT in AML
Given the high occurrence of JAK dysregulation in MPN, it may be suggested that JAK/STAT pathway dysregulation plays a role in the pathogenesis of secondary AML. Yet, JAK/STAT dysregulation may not be exclusive to secondary AML, as elevated JAK and STAT levels have been observed in patients with de novo AML. Since p-JAK levels are increased in patients with AML, and the JAK2 V617F mutation is present in only a small percentage of these patients, this specific mutation cannot be exclusively responsible for JAK dysregulation. It is possible that the classic V617F mutation, when present, may function either as a driver mutation in the initial stages of AML or as a passenger mutation in later stages by virtue of increased genomic instability and mutation load. Besides the JAK2 V617F mutation, several A recent study found elevated levels of activated p-JAK2 in bone marrow samples from a large cohort of AML patients (n = 77). Elevated p-JAK2 correlated with high white blood cell count, low platelet count, and shorter survival in patients with either de novo or secondary AML (Fig. 3) The Role of JAK in AML 9 ruxolitinib, potentiates FLT3 inhibition, leading to a significant increase in cytotoxicity in in vitro FLT3-positive stromal models (64) . Some JAK2 inhibitors (e.g. CEP-701, SB518, TG101348) in development do have activity against FLT3, but the consequences of dual FLT3/JAK2 inhibition have not been fully studied outside of MPNs (11) . Furthermore, activating mutations in JAK1 have been described at low rates (1-2%) in AML and therefore JAK2 inhibitors that also target JAK1, such as ruxolitinib and CYT387 may be the most useful in this context (53) .
Clinical Results: Patient Data and Therapeutic Toxicity
Early evidence regarding the efficacy of JAK inhibition in the treatment of AML shows promise. In a phase II clinical trial, 23 patients with relapsed or refractory AML, ALL, MDS, or CML (median age, 68 years) were administered ruxolitinib and were initially evaluated after one cycle of therapy or 28 days This study was expanded to include a total of 38 patients; 18 had secondary AML and 10 had de novo AML. The JAK2 V617F mutation was observed in 12 patients, three with de novo AML, seven with secondary AML, and two with MDS (66) . Clinical benefit (CR, PR, or SD) was observed in 15 patients, although it was limited to SD in 12. Of the three patients achieving CR or PR, all had secondary AML, which was positive for JAK2 V617F in two. In these three patients, ruxolitinib not only produced a response but also reduced spleen size. Ruxolitinib therapy was well tolerated, with minimal grade ≥3 toxic effects in this heavily pretreated population. This may represent a potential treatment option for patients with refractory disease.
In the COMFORT trials, anemia and thrombocytopenia were the most frequently reported adverse events in the ruxolitinib arms of both studies, though rarely led to treatment discontinuation and were generally manageable with dose modifications and/or transfusions (24, 25) . Accordingly, patients with AML treated with JAK1/2 inhibitors may develop or experience worsening of their anemia and thrombocytopenia. As the JAK/STAT pathway is a major regulator of erythropoiesis, it is anticipated that JAK1/2 inhibitor therapy would lead to some myelosuppression, including anemia. The ultimate goal of such strategies is "personalized medicine," wherein clinicians will be able to optimize AML therapy based on each individual's genomic data. Under such an approach, identification of tyrosine kinase mutations in AML patients may suggest the use of specific small-molecule kinase inhibitors. Moreover, if dysregulation of a specific pathway were identified treatment with an appropriate inhibitor would represent a rational approach (73, 74) . Given recent advances in our understanding of genomic pathways as well as the economic feasibility of individual sequencing, it is reasonable to foresee a time when clinicians will be able to personalize the therapy offered to individual patients with AML.
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